• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
BAI Yan, GUO Xinyao, QIN Qiliang, YAN Fang. Advances in research on mechanism of lactate dehydrogenase B in tumors[J]. Journal of China Pharmaceutical University, 2023, 54(2): 172-179. DOI: 10.11665/j.issn.1000-5048.20221112001
Citation: BAI Yan, GUO Xinyao, QIN Qiliang, YAN Fang. Advances in research on mechanism of lactate dehydrogenase B in tumors[J]. Journal of China Pharmaceutical University, 2023, 54(2): 172-179. DOI: 10.11665/j.issn.1000-5048.20221112001
shu

Advances in research on mechanism of lactate dehydrogenase B in tumors

  • 1.

    Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009

  • 2.

    Food and Drug Inspection and Testing Center,Huangnan Tibetan Autonomous Prefecture of Qinghai Province,Tongren 811399, China

Funds: This study was supported by the National Natural Science Foundation of China (No.82173956)
More Information
  • Received Date: November 11, 2022
  • Revised Date: March 03, 2023
    Graphical Abstract
    • Abstract
  • Increased glycolysis is a major feature of metabolic reprogramming in cancer.Glycolysis provides not only energy for cancer cells but also necessary precursors for biosynthesis, which is important for promoting tumor growth.Cancer cells meet their own needs by regulating glycolytic enzymes, which play an active role in promoting cancer survival, metastasis, and invasion.Lactate dehydrogenase (LDH), as a key enzyme in glycolysis, consists of two subunits: lactate dehydrogenase A (LDHA) and lactate dehydrogenase B (LDHB).LDHA is known to play a key role in aerobic glycolysis and has been extensively studied, whereas less has been done on LDHB.However, at present, more and more reports have revealed the important effects of LDHB on the progression of various cancers.A large number of studies have shown that LDHB is abnormally expressed in a variety of cancers, which is related to the malignant progression of tumors.The article reviews the research progress of LDHB in recent ten years, including its regulatory mechanism in tumor, its relationship with cancer development and its role as a biomarker in clinical diagnosis of cancer, which provides some insight for further investigation of the mechanism of LDHB in cancer research.
    • FullText(HTML)
    • References (52)
  • [1]
    Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth[J]. Genes Dev, 2009, 23(5): 537-548.
    [2]
    Warburg O. On the origin of cancer cells[J]. Science, 1956, 123(3191): 309-314.
    [3]
    Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis[J]? Nat Rev Cancer, 2004, 4(11): 891-899.
    [4]
    Xu RH, Pelicano H, Zhou Y, et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia[J]. Cancer Res, 2005, 65(2): 613-621.
    [5]
    de la Cruz-López KG, Castro-Mu?oz LJ, Reyes-Hernández DO, et al. Lactate in the regulation of tumor microenvironment and therapeutic approaches[J]. Front Oncol, 2019, 9: 1143.
    [6]
    Feng YB, Xiong YL, Qiao TY, et al. Lactate dehydrogenase A: a key player in carcinogenesis and potential target in cancer therapy[J]. Cancer Med, 2018, 7(12): 6124-6136.
    [7]
    McCleland ML, Adler AS, Deming L, et al. Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas[J]. Clin Cancer Res, 2013, 19(4): 773-784.
    [8]
    Wang RG, Li JB, Zhang CJ, et al. Lactate dehydrogenase B is required for pancreatic cancer cell immortalization through activation of telomerase activity[J]. Front Oncol, 2022, 12: 821620.
    [9]
    Liu J, Chen G, Liu Z, et al. Aberrant FGFR tyrosine kinase signaling enhances the Warburg effect by reprogramming LDH isoform expression and activity in prostate cancer[J]. Cancer Res, 2018, 78(16): 4459-4470.
    [10]
    Urbańska K, Orzechowski A. Unappreciated role of LDHA and LDHB to control apoptosis and autophagy in tumor cells[J]. Int J Mol Sci, 2019, 20(9): 2085.
    [11]
    Moreno-Sánchez R, Rodríguez-Enríquez S, Marín-Hernández A, et al. Energy metabolism in tumor cells[J]. FEBS J, 2007, 274(6): 1393-1418.
    [12]
    Cascardo F, Anselmino N, Páez A, et al. HO-1 modulates aerobic glycolysis through LDH in prostate cancer cells[J]. Antioxidants (Basel), 2021, 10(6): 966.
    [13]
    Mishra D, Banerjee D. Lactate dehydrogenases as metabolic links between tumor and stroma in the tumor microenvironment[J]. Cancers (Basel), 2019, 11(6): 750.
    [14]
    Liu HB, Li S, Wang XY, et al. DNA methylation dynamics: identification and functional annotation[J]. Brief Funct Genomics, 2016, 15(6): 470-484.
    [15]
    Cui JJ, Quan M, Jiang WH, et al. Suppressed expression of LDHB promotes pancreatic cancer progression via inducing glycolytic phenotype[J]. Med Oncol, 2015, 32(5): 143.
    [16]
    Zhang W, Tong D, Liu F, et al. RPS7 inhibits colorectal cancer growth via decreasing HIF-1α-mediated glycolysis[J]. Oncotarget, 2016, 7(5): 5800-5814.
    [17]
    Jiang P, Huang M, Qi WW, et al. FUBP1 promotes neuroblastoma proliferation via enhancing glycolysis — a new possible marker of malignancy for neuroblastoma[J]. J Exp Clin Cancer Res, 2019, 38(1): 400.
    [18]
    Nam K, Oh S, Shin I. Ablation of CD44 induces glycolysis-to-oxidative phosphorylation transition via modulation of the c-Src-Akt-LKB1-AMPKα pathway[J]. Biochem J, 2016, 473(19): 3013-3030.
    [19]
    Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene[J]. Cell, 1999, 98(3): 295-303.
    [20]
    Zha XJ, Wang F, Wang Y, et al. Lactate dehydrogenase B is critical for hyperactive mTOR-mediated tumorigenesis[J]. Cancer Res, 2011, 71(1): 13-18.
    [21]
    Hao JS, Zhu CJ, Yan BY, et al. Stimulation of KLF14/PLK1 pathway by thrombin signaling potentiates endothelial dysfunction in type 2 diabetes mellitus[J]. Biomed Pharmacother, 2018, 99: 859-866.
    [22]
    Wu GY, Yuan SC, Chen ZP, et al. The KLF14 transcription factor regulates glycolysis by downregulating LDHB in colorectal cancer[J]. Int J Biol Sci, 2019, 15(3): 628-635.
    [23]
    Hill M, Tran N. miRNA interplay: mechanisms and consequences in cancer[J]. Dis Model Mech, 2021, 14(4): dmm047662.
    [24]
    Kumar S, Xie H, Scicluna P, et al. MiR-375 regulation of LDHB plays distinct roles in polyomavirus-positive and-negative merkel cell carcinoma[J]. Cancers (Basel), 2018, 10(11): 443.
    [25]
    Wang JM, Jiang JY, Zhang DL, et al. HYOU1 facilitates proliferation, invasion and glycolysis of papillary thyroid cancer via stabilizing LDHB mRNA[J]. J Cell Mol Med, 2021, 25(10): 4814-4825.
    [26]
    Yang H, Jiang Z, Wang S, et al. Long non-coding small nucleolar RNA host genes in digestive cancers[J]. Cancer Med, 2019, 8(18): 7693-7704.
    [27]
    La Montagna M, Shi L, Magee P, et al. AMPKα loss promotes KRAS-mediated lung tumorigenesis[J]. Cell Death Differ, 2021, 28(9): 2673-2689.
    [28]
    Liu J, Li Y, Chen XQ, et al. rs11046147 mutation in the promoter region of lactate dehydrogenase-B as a potential predictor of prognosis in triple-negative breast cancer[J]. Cancer Commun, 2020, 40(6): 279-282.
    [29]
    Liu JN, Wang Q, Kang YJ, et al. Unconventional protein post-translational modifications: the helmsmen in breast cancer[J]. Cell Biosci, 2022, 12(1): 22.
    [30]
    Shi L, Yan H, An SX, et al. SIRT5-mediated deacetylation of LDHB promotes autophagy and tumorigenesis in colorectal cancer[J]. Mol Oncol, 2019, 13(2): 358-375.
    [31]
    Cheng AX, Zhang P, Wang B, et al. Aurora-A mediated phosphorylation of LDHB promotes glycolysis and tumor progression by relieving the substrate-inhibition effect[J]. Nat Commun, 2019, 10(1): 5566.
    [32]
    Wang L. miR-141-3p overexpression suppresses the malignancy of osteosarcoma by targeting FUS to degrade LDHB[J]. Biosci Rep, 2020, 40(6): BSR20193404.
    [33]
    Luo Y, Yang ZL, Li DQ, et al. LDHB and FABP4 are associated with progression and poor prognosis of pancreatic ductal adenocarcinomas[J]. Appl Immunohistochem Mol Morphol, 2017, 25(5): 351-357.
    [34]
    Yustisia I, Amriani R, Cangara H, et al. High expression of FBP1 and LDHB in fibroadenomas and invasive breast cancers[J]. Breast Dis, 2021, 40(4): 251-256.
    [35]
    Deng HB, Gao YY, Trappetti V, et al. Targeting lactate dehydrogenase B-dependent mitochondrial metabolism affects tumor initiating cells and inhibits tumorigenesis of non-small cell lung cancer by inducing mtDNA damage[J]. Cell Mol Life Sci, 2022, 79(8): 445.
    [36]
    Li C, Chen Y, Bai P, et al. LDHB may be a significant predictor of poor prognosis in osteosarcoma[J]. Am J Transl Res, 2016, 8(11): 4831-4843.
    [37]
    McCleland ML, Adler AS, Shang Y, et al. An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer[J]. Cancer Res, 2012, 72(22): 5812-5823.
    [38]
    Brisson L, Bański P, Sboarina M, et al. Lactate dehydrogenase B controls lysosome activity and autophagy in cancer[J]. Cancer Cell, 2016, 30(3): 418-431.
    [39]
    Sheng KH, Yao YC, Chuang SS, et al. Search for the tumor-related proteins of transition cell carcinoma in Taiwan by proteomic analysis[J]. Proteomics, 2006, 6(3): 1058-1065.
    [40]
    Chen RH, Zhou X, Yu ZH, et al. Low expression of LDHB correlates with unfavorable survival in hepatocellular carcinoma: strobe-compliant article[J]. Medicine, 2015, 94(39): e1583.
    [41]
    Rosso M, Lapyckyj L, Besso MJ, et al. Characterization of the molecular changes associated with the overexpression of a novel epithelial cadherin splice variant mRNA in a breast cancer model using proteomics and bioinformatics approaches: identification of changes in cell metabolism and an increased expression of lactate dehydrogenase B[J]. Cancer Metab, 2019, 7: 5.
    [42]
    Fu DY, Li J, Wei JL, et al. HMGB2 is associated with malignancy and regulates Warburg effect by targeting LDHB and FBP1 in breast cancer[J]. Cell Commun Signal, 2018, 16(1): 8.
    [43]
    Li LF, Wang YF, Wang Q, et al. High developmental pluripotency-associated 4 expression promotes cell proliferation and glycolysis, and predicts poor prognosis in non-small- cell lung cancer[J]. Mol Med Report, 2019,20(1): 445-454.
    [44]
    Qing Y, Dong L, Gao L, et al. R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis[J]. Mol Cell, 2021, 81(5): 922-939. e9.
    [45]
    Du Y, Zhang MJ, Li LL, et al. ATPR triggers acute myeloid leukaemia cells differentiation and cycle arrest via the RARα/LDHB/ERK-glycolysis signalling axis[J]. J Cell Mol Med, 2020, 24(12): 6952-6965.
    [46]
    Feng MY, Xiong GB, Cao Z, et al. LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer[J]. J Exp Clin Cancer Res, 2018, 37(1): 274.
    [47]
    Hong SM, Lee YK, Park I, et al. Lactic acidosis caused by repressed lactate dehydrogenase subunit B expression down-regulates mitochondrial oxidative phosphorylation via the pyruvate dehydrogenase (PDH)-PDH kinase axis[J]. J Biol Chem, 2019, 294(19): 7810-7820.
    [48]
    Kim JH, Kim EL, Lee YK, et al. Decreased lactate dehydrogenase B expression enhances claudin 1-mediated hepatoma cell invasiveness via mitochondrial defects[J]. Exp Cell Res, 2011, 317(8): 1108-1118.
    [49]
    Sun W, Zhang X, Ding X, et al. Lactate dehydrogenase B is associated with the response to neoadjuvant chemotherapy in oral squamous cell carcinoma[J]. PLoS One, 2015, 10(5): e0125976.
    [50]
    Koh YW, Lee SJ, Park SY. Prognostic significance of lactate dehydrogenase B according to histologic type of non-small-cell lung cancer and its association with serum lactate dehydrogenase[J]. Pathol Res Pract, 2017, 213(9): 1134-1138.
    [51]
    Li C, Chen S, Jia WM, et al. Identify metabolism-related genes IDO1, ALDH2, NCOA2, SLC7A5, SLC3A2, LDHB, and HPRT1 as potential prognostic markers and correlate with immune infiltrates in head and neck squamous cell carcinoma[J]. Front Immunol, 2022, 13: 955614.
    [52]
    de Haas T, Hasselt N, Troost D, et al. Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression[J]. Clin Cancer Res, 2008, 14(13): 4154-4160.
    • Related Articles

  • Related Articles

    [1]ZHANG Zhixing, DENG Hua, TANG Yun. Applications and challenges of artificial intelligence in the development of anticancer peptides[J]. Journal of China Pharmaceutical University, 2024, 55(3): 347-356. DOI: 10.11665/j.issn.1000-5048.2024040201
    [2]HU Zi’ang, GAO Liming, YU Wenying. Advances in the application of artificial intelligence in nucleic acid drug development[J]. Journal of China Pharmaceutical University, 2024, 55(3): 335-346. DOI: 10.11665/j.issn.1000-5048.2024033101
    [3]ZENG Hao, WU Guozhen, ZOU Wuxin, WANG Zhe, SONG Jianfei, SHI Hui, WANG Xiaojian, HOU Tingjun, DENG Yafeng. Optimization of Menin inhibitors based on artificial intelligence-driven molecular factory technology[J]. Journal of China Pharmaceutical University, 2024, 55(3): 326-334. DOI: 10.11665/j.issn.1000-5048.2024040904
    [4]TANG qian, CHEN Roufen, SHEN Zheyuan, CHI Xinglong, CHE Jinxin, DONG Xiaowu. Research progress of artificial intelligence-based small molecule generation models in drug discovery[J]. Journal of China Pharmaceutical University, 2024, 55(3): 295-305. DOI: 10.11665/j.issn.1000-5048.2024031501
    [5]XUE Feng, FENG Shuo, LI Jing. Application and prospect of artificial intelligence in antimicrobial peptides screening[J]. Journal of China Pharmaceutical University, 2023, 54(3): 314-322. DOI: 10.11665/j.issn.1000-5048.2023030901
    [6]GU Zhihao, GUO Wenhao, YAO Hequan, LI Xuanyi, LIN Kejiang. Research progress of the screening and generation of lead compounds based on artificial intelligence model[J]. Journal of China Pharmaceutical University, 2023, 54(3): 294-304. DOI: 10.11665/j.issn.1000-5048.2023042201
    [7]YU Zehao, ZHANG Leiming, ZHANG Mengna, DAI Zhiqi, PENG Chengbin, ZHENG Siming. Artificial intelligence-based drug development: current progress and future challenges[J]. Journal of China Pharmaceutical University, 2023, 54(3): 282-293. DOI: 10.11665/j.issn.1000-5048.2023041003
    [8]WANG Chao, XIAO Fu, LI Miaozhu, PAN Ying, DING Xiao, REN Feng, ZHAVORONKOV Alex, WANG Yazhou. Application progress of artificial intelligence in the screening and identification of drug targets[J]. Journal of China Pharmaceutical University, 2023, 54(3): 269-281. DOI: 10.11665/j.issn.1000-5048.2023041102
    [9]YAN Fangrong. Application and advance of artificial intelligence in biomedical field[J]. Journal of China Pharmaceutical University, 2023, 54(3): 263-268. DOI: 10.11665/j.issn.1000-5048.2023030304
    [10]Zhang Zunjian, Yu Shuqin, Xiang Bingren, An Dengkui. A New Artificial Neural Network Model:Combined Counter-Back Propagation and its Application[J]. Journal of China Pharmaceutical University, 1996, (11).

  • Cited by

    Periodical cited type(1)

    1. 赵倩，魏宇，郭凯敏，王文佳，周水平，孙鹤，方坚松，胡蕴慧. 人工智能结合生物网络对“养血清脑制剂”和“逍遥丸”组方的优化及验证. 中药药理与临床. 2024(04): 27-33 .

    Other cited types(3)

Catalog

    Get Citation
    PDF
    XML
    Article views (760) PDF downloads (840) Cited by(4)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：295209

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return